Pages that link to "Q670131"
Jump to navigation
Jump to search
The following pages link to simvastatin (Q670131):
Displayed 50 items.
- World Health Organization Model List of Essential Medicines (Q37155) (← links)
- clarithromycin (Q118551) (← links)
- arteriosclerosis (Q184559) (← links)
- erythromycin (Q213511) (← links)
- (S)-(−)-colchicine (Q326224) (← links)
- cyclosporine (Q367700) (← links)
- gemfibrozil (Q384295) (← links)
- Ketoconazole (Q407883) (← links)
- amiodarone (Q410061) (← links)
- verapamil (Q410291) (← links)
- carbamazepin (Q410412) (← links)
- itraconazole (Q411229) (← links)
- amlodipine (Q411347) (← links)
- fluconazole (Q411478) (← links)
- eltrombopag (Q411588) (← links)
- 3-hydroxy-3-methylglutaryl-CoA reductase (Q415607) (← links)
- (2R)-daptomycin (Q418747) (← links)
- danazol (Q419652) (← links)
- fenofibrate (Q419724) (← links)
- diltiazem (Q422229) (← links)
- ritonavir (Q422618) (← links)
- bezafibrate (Q577387) (← links)
- coronary artery disease (Q844935) (← links)
- posaconazole (Q906453) (← links)
- ranolazine (Q907104) (← links)
- toxic shock syndrome (Q1128440) (← links)
- cerebral hemorrhage (Q1368943) (← links)
- hypertriglyceridemia (Q1467339) (← links)
- ciprofibrate (Q3496452) (← links)
- cobicistat (Q5138908) (← links)
- ezetimibe/simvastatin (Q5423256) (← links)
- idelalisib (Q5908266) (← links)
- simvastatin/sitagliptin (Q9635292) (← links)
- familial hyperlipidemia (Q18554145) (← links)
- The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells (Q21093314) (← links)
- Enteric microbiome metabolites correlate with response to simvastatin treatment (Q21135141) (← links)
- Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo (Q21261269) (← links)
- Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses (Q21560808) (← links)
- Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment (Q21561017) (← links)
- response to simvastatin (Q22274484) (← links)
- Molecular mechanisms underlying the inhibition of IFN-γ-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs (Q24338459) (← links)
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial (Q24569666) (← links)
- Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice (Q24597354) (← links)
- Hair growth defects in Insig-deficient mice caused by cholesterol precursor accumulation and reversed by simvastatin (Q24624413) (← links)
- Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease (Q24629942) (← links)
- Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial (Q24647676) (← links)
- Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease (Q24673755) (← links)
- Taking simvastatin in the morning compared with in the evening: randomised controlled trial (Q24677046) (← links)
- Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin (Q24679132) (← links)
- The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393] (Q24793837) (← links)